References
- 국가암정보센터. 3대 주요암의 5년상대생존율 국제비교{online} {cited 2008 May 14};Avaliable from:URL: http://www.cancer.go.kr/cms/statics/stat/1194001_1611.html
- 세계보건기구(WHO). Screening and early detection of cancer {online}{cited 2008 March 31}; Avaliable from:URL: http://www.who.int/cancer/detection/en
- Yasuda S, Ide M, Fujii H, Nakahara T, Mochizuki Y, Takahashi W, et al. Application of positron emission tomography imaging to cancer screening. Br J Cancer 2000;83:1607-11 https://doi.org/10.1054/bjoc.2000.1496
- Smith RA, Cokkinides V, Eyre HJ. American Cancer Society guidelines for the early detection of cancer, 2003. CA Cancer J Clin 2003;53:27-43 https://doi.org/10.3322/canjclin.53.1.27
- 세계보건기구(WHO). Screening for various cancer{online} {cited 2008 March 31}; Avaliable from:URL: http://www.who.int/cancer/detection/variouscancer/en/index.html
- Czernin J, Allen-Auerbach M, Schelbert HR. Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006. J Nucl Med 2007;48 Suppl 1:78S-88S
-
Yasuda S, Shohtsu A. Cancer screening with whole-body
$^{18}F-fluorodeoxyglucose$ positron-emission tomography. Lancet 1997; 350:1819 https://doi.org/10.1016/S0140-6736(97)24051-1 - Basu S, Houseni M, Alavi A. Significance of incidental fluorodeoxyglucose uptake in the parotid glands and its impact on patient management. Nucl Med Commun 2008;29:367-73 https://doi.org/10.1097/MNM.0b013e3282f8147a
- Bicik I, Bauerfeind P, Breitbach T, von Schulthess GK, Fried M. Inflammatory bowel disease activity measured by positronemission tomography. Lancet 1997;350:262
-
Kresnik E, Gallowitsch HJ, Mikosch P, Wurtz F, Alberer D, Hebenstreit A, et al.
$^{18}F-FDG$ positron emission tomography in the early diagnosis of enterocolitis: preliminary results. Eur J Nucl Med Mol Imaging 2002;29:1389-92 https://doi.org/10.1007/s00259-002-0901-7 - Minamimoto R, Senda M, Uno K, Jinnouchi S, Iinuma T, Ito K, et al. Performance profile of FDG-PET and PET/CT for cancer screening on the basis of a Japanese Nationwide Survey. Ann Nucl Med 2007;21:481-98 https://doi.org/10.1007/s12149-007-0061-8
- Yasuda S, Ide M. PET and cancer screening. Ann Nucl Med 2005;19:167-77 https://doi.org/10.1007/BF02984601
- Wang G, Lau EW, Shakher R, Rischin D, Ware RE, Hong E, et al. How do oncologists deal with incidental abnormalities on whole-body fluorine-18 fluorodeoxyglucose PET/CT? Cancer 2007;109:117-24 https://doi.org/10.1002/cncr.22370
- Even-Sapir E, Lerman H, Gutman M, Lievshitz G, Zuriel L, Polliack A, et al. The presentation of malignant tumours and pre-malignant lesions incidentally found on PET-CT. Eur J Nucl Med Mol Imaging 2006;33:541-52 https://doi.org/10.1007/s00259-005-0056-4
- Ishimori T, Patel PV, Wahl RL. Detection of unexpected additional primary malignancies with PET/CT. J Nucl Med 2005; 46:752-7
-
Zhuang H, Alavi A.
$^{18}F-fluorodeoxyglucose$ positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med 2002;32:47-59 https://doi.org/10.1053/snuc.2002.29278 - Agress H, Jr., Cooper BZ. Detection of clinically unexpected malignant and premalignant tumors with whole-body FDG PET: histopathologic comparison. Radiology 2004;230:417-22 https://doi.org/10.1148/radiol.2302021685
- Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med 2001;42:1S-93S
- 대한핵의학회. 핵의학검사 통계자료(2007){ serial online} {cited 2008 April 1}; Avaliable from:URL: http://www.ksnm.or.kr/member/pds/stat/index.html
- Ono K, Ochiai R, Yoshida T, Kitagawa M, Omagari J, Kobayashi H, et al. The detection rates and tumor clinical/ pathological stages of whole-body FDG-PET cancer screening. Ann Nucl Med 2007;21:65-72 https://doi.org/10.1007/BF03034001
-
Kojima S, Zhou B, Teramukai S, Hara A, Kosaka N, Matsuo Y, et al. Cancer screening of healthy volunteers using whole-body
$^{18}F-FDG-PET$ scans: the Nishidai clinic study. Eur J Cancer 2007;43:1842-8 https://doi.org/10.1016/j.ejca.2007.05.010 - Ghotbi N, Iwanaga M, Ohtsuru A, Ogawa Y, Yamashita S. Cancer screening with whole-body PET/CT for healthy asymptomatic people in Japan: re-evaluation of its test validity and radiation exposure. Asian Pac J Cancer Prev 2007;8:93-7
- Ide M. Cancer screening with FDG-PET. Q J Nucl Med Mol Imaging 2006;50:23-7
- Schoder H, Larson SM. Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med 2004;34: 274-92 https://doi.org/10.1053/j.semnuclmed.2004.06.004
-
Cook GJ, Wegner EA, Fogelman I. Pitfalls and artifacts in
$^{18}F-FDG$ PET and PET/CT oncologic imaging. Semin Nucl Med 2004;34:122-33 https://doi.org/10.1053/j.semnuclmed.2003.12.003 - Powles T, Murray I, Brock C, Oliver T, Avril N. Molecular positron emission tomography and PET/CT imaging in urological malignancies. Eur Urol 2007;51:1511-20 https://doi.org/10.1016/j.eururo.2007.01.061
- Powles T, Murray I, Brock C, Oliver T, Avril N. Molecular positron emission tomography and PET/CT imaging in urological malignancies. Eur Urol 2007;51; discussion 1520-1 https://doi.org/10.1016/j.eururo.2007.01.062
- Weckesser M, Schober O. Is whole-body FDG-PET valuable for health screening? Against. Eur J Nucl Med Mol Imaging 2005; 32:342-3 https://doi.org/10.1007/s00259-005-1775-2
- Abouzied MM, Crawford ES, Nabi HA. 18F-FDG imaging: pitfalls and artifacts. J Nucl Med Technol 2005;33:145-55
- Abouzied MM, Crawford ES, Nabi HA. 18F-FDG imaging: pitfalls and artifacts. J Nucl Med Technol 2005;33; quiz 62-3
- Aquino SL, Halpern EF, Kuester LB, Fischman AJ. FDG-PET and CT features of non-small cell lung cancer based on tumor type. Int J Mol Med 2007;19:495-9
- Stahl A, Ott K, Weber WA, Becker K, Link T, Siewert JR, et al. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging 2003;30:288-95 https://doi.org/10.1007/s00259-002-1029-5
- Fischer BM, Olsen MW, Ley CD, Klausen TL, Mortensen J, Hojgaard L, et al. How few cancer cells can be detected by positron emission tomography? A frequent question addressed by an in vitro study. Eur J Nucl Med Mol Imaging 2006;33:697-702 https://doi.org/10.1007/s00259-005-0038-6
-
Shoda H, Kakugawa Y, Saito D, Kozu T, Terauchi T, Daisaki H, et al. Evaluation of
$^{18}F-2-deoxy-2-fluoro-glucose$ positron emission tomography for gastric cancer screening in asymptomatic individuals undergoing endoscopy. Br J Cancer 2007; 97:1493-8 https://doi.org/10.1038/sj.bjc.6604062 -
Mochiki E, Kuwano H, Katoh H, Asao T, Oriuchi N, Endo K. Evaluation of
$^{18}F-2-deoxy-2-fluoro-D-glucose$ positron emission tomography for gastric cancer. World J Surg 2004;28:247-53 https://doi.org/10.1007/s00268-003-7191-5 - Mukai K, Ishida Y, Okajima K, Isozaki H, Morimoto T, Nishiyama S. Usefulness of preoperative FDG-PET for detection of gastric cancer. Gastric Cancer 2006;9:192-6 https://doi.org/10.1007/s10120-006-0374-7
- Subhas N, Patel PV, Pannu HK, Jacene HA, Fishman EK, Wahl RL. Imaging of pelvic malignancies with in-line FDG PET-CT: case examples and common pitfalls of FDG PET. Radiographics 2005;25:1031-43 https://doi.org/10.1148/rg.254045155
-
Choi JY, Lee KS, Kim HJ, Shim YM, Kwon OJ, Park K, et al. Focal thyroid lesions incidentally identified by integrated
$^{18}F-FDG PET/CT$ : clinical significance and improved characterization. J Nucl Med 2006;47:609-15 - Van den Bruel A, Maes A, De Potter T, Mortelmans L, Drijkoningen M, Van Damme B, et al. Clinical relevance of thyroid fluorodeoxyglucose-whole body positron emission tomography incidentaloma. J Clin Endocrinol Metab 2002;87: 1517-20 https://doi.org/10.1210/jc.87.4.1517
-
Kang KW, Kim SK, Kang HS, Lee ES, Sim JS, Lee IG, et al. Prevalence and risk of cancer of focal thyroid incidentaloma identified by
$^{18}F-fluorodeoxyglucose$ positron emission tomography for metastasis evaluation and cancer screening in healthy subjects. J Clin Endocrinol Metab 2003;88:4100-4 https://doi.org/10.1210/jc.2003-030465 -
Kim TY, Kim WB, Ryu JS, Gong G, Hong SJ, Shong YK.
$^{18}F-fluorodeoxyglucose$ uptake in thyroid from positron emission tomogram (PET) for evaluation in cancer patients: high prevalence of malignancy in thyroid PET incidentaloma. Laryngoscope 2005;115:1074-8 https://doi.org/10.1097/01.MLG.0000163098.01398.79 -
Nam SY, Roh JL, Kim JS, Lee JH, Choi SH, Kim SY. Focal uptake of
$^{18}F-fluorodeoxyglucose$ by thyroid in patients with nonthyroidal head and neck cancers. Clin Endocrinol (Oxf) 2007;67:135-9 https://doi.org/10.1111/j.1365-2265.2007.02850.x - Cohen MS, Arslan N, Dehdashti F, Doherty GM, Lairmore TC, Brunt LM, et al. Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose-positron emission tomography. Surgery 2001;130:941-6 https://doi.org/10.1067/msy.2001.118265
-
Bogsrud TV, Karantanis D, Nathan MA, Mullan BP, Wiseman GA, Collins DA, et al. The value of quantifying
$^{18}F-FDG$ uptake in thyroid nodules found incidentally on whole-body PET-CT. Nucl Med Commun 2007;28:373-81 https://doi.org/10.1097/MNM.0b013e3280964eae